CLINICAL TRIALS PROFILE FOR OSIMERTINIB MESYLATE

All Clinical Trials for OSIMERTINIB MESYLATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT04798638 ↗	A Study to Assess the Effect of Food on the Pharmacokinetics of TY-9591 in Healthy Volunteers	Recruiting	TYK Medicines, Inc	Phase 1	2021-05-01	To assess the pharmacokinetics of TY-9591 tablets and Osimertinib Mesylate tablets after a single fasting administration and the effect of food on the pharmacokinetics of TY-9591 tablets in healthy volunteers.
NCT05020457 ↗	A Phase II/III Study of SI-B001 in Combination With Osimertinib in the Treatment of EGFR/ALK WT Recurrent and Metastatic NSCLC	Not yet recruiting	Sichuan Baili Pharmaceutical Co., Ltd.	Phase 2/Phase 3	2021-10-01	Main purpose: 1. To explore the efficacy of SI-B001 at RP2D obtained in phase I clinical trial and single low dose combined with chemotherapy in patients with locally advanced or metastatic NSCLC. 2. To explore the safety and tolerability of SI-B001 in patients with locally advanced or metastatic lung cancer (NSCLC) at RP2D obtained in phase I clinical trial and single-dose low-dose combination chemotherapy, and to select the optimal dose (combined with RP2D) and mode of SI-B001 combined with chemotherapy.
NCT05020769 ↗	A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of SI-B001 in Combination With Osimertinib Mesylate Tablets in the Treatment of Recurrent and Metastatic Non- Small Cell Lung Cancer	Not yet recruiting	Sichuan Baili Pharmaceutical Co., Ltd.	Phase 2/Phase 3	2021-10-01	Main purpose: 1. To explore the efficacy of SI-B001 at RP2D obtained in phase I clinical trial and single low dose combined with Osimertinib in patients with locally advanced or metastatic NSCLC. 2. To explore the safety and tolerability of SI-B001 in patients with locally advanced or metastatic lung cancer (NSCLC) at RP2D obtained in phase I clinical trial and single-dose low-dose combination chemotherapy, and to select the optimal dose (combined with RP2D) and mode of SI-B001 combined with Osimertinib.
NCT05085054 ↗	Salvage Surgery Following Downstaging of Advanced Non-small Cell Lung Cancer by Targeted Therapy (SDANT)	Not yet recruiting	Wuhan Union Hospital, China	Phase 2	2021-11-01	The purpose of this study is to evaluate the safety and efficacy of neoadjuvant targeted therapy followed by surgery in participants with advanced non-small cell lung cancer.
NCT05284994 ↗	TQ-B3525 Tablets Combined With Osimertinib Mesylate Tablets in the Treatment of Advanced Non-Small Cell Lung Cancer	Recruiting	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Phase 1/Phase 2	2022-03-11	TQ-B3525 tablet is a new α/δ dual inhibitor phosphatidylinositol 3-kinase inhibitor developed by Chia Tai Tianqing pharmaceutical Group Co., Ltd. It can overcome the drug resistance problem caused by the up-regulation of phosphatidylinositol 3-kinase α subunit activity caused by the single inhibition of phosphatidylinositol 3-kinase δ subunit. This study is a single-arm, open-label, multi-cohort, multi-center clinical study of the safety and efficacy of TQ-B3525 tablets combined with osimertinib in subjects with advanced non-small cell lung cancer, aiming to evaluate TQ-B3525 tablets combined with osimertinib, the safety, tolerability, and efficacy of the treatment of patients with advanced non-small cell lung cancer who have failed epidermal growth factor receptor inhibitor therapy, while exploring the efficacy, resistance mechanism, and safety in the dose escalation phase biomarkers.
NCT05816252 ↗	A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)	Not yet recruiting	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.	Phase 2	2023-04-12	The purpose of this study is to evaluate the safety, tolerability and objective response rate of SKB264 as combination with therapy in subjects with advanced or metastatic non-small cell lung cancer.

Clinical Trial Conditions for OSIMERTINIB MESYLATE

Condition Name

Condition Name for OSIMERTINIB MESYLATE
Intervention	Trials
Non-Small Cell Lung Cancer	6
Non Small Cell Lung Cancer	2
EGFR Positive Non-small Cell Lung Cancer	1
Stage IIIC Non-Small Cell Lung Cancer	1

Condition MeSH

Condition MeSH for OSIMERTINIB MESYLATE
Intervention	Trials
Carcinoma, Non-Small-Cell Lung	11
Lung Neoplasms	7

Clinical Trial Locations for OSIMERTINIB MESYLATE

Trials by Country

Trials by Country for OSIMERTINIB MESYLATE
Location	Trials
China	16
Japan	9

Clinical Trial Progress for OSIMERTINIB MESYLATE

Clinical Trial Phase

Clinical Trial Phase for OSIMERTINIB MESYLATE
Clinical Trial Phase	Trials
PHASE3	1
PHASE2	4
PHASE1	2

Clinical Trial Status

Clinical Trial Status for OSIMERTINIB MESYLATE
Clinical Trial Phase	Trials
RECRUITING	6
Not yet recruiting	5
NOT_YET_RECRUITING	2

Clinical Trial Sponsors for OSIMERTINIB MESYLATE

Sponsor Name

Sponsor Name for OSIMERTINIB MESYLATE
Sponsor	Trials
Sichuan Baili Pharmaceutical Co., Ltd.	4
Klus Pharma Inc.	1
Suzhou Genhouse Bio Co., Ltd.	1

Sponsor Type

Sponsor Type for OSIMERTINIB MESYLATE
Sponsor	Trials
Industry	12
Other	4

Last updated: April 27, 2026

Osimertinib Mesylate: Clinical Trials Update, Market Analysis, and Projection (Global)

What is osimertinib mesylate’s clinical-trial status and what programs are driving near-term timelines?

Osimertinib mesylate is the marketed EGFR TKI by AstraZeneca (Tagrisso). Clinical activity through 2025 clusters around (1) earlier lines and expanded populations in NSCLC, (2) adjuvant and peri-operative strategies, and (3) combinations that target resistance mechanisms (MET, HER2, VEGF, and immune pathways). Trial volumes remain highest in non-small cell lung cancer (NSCLC), with ongoing studies spanning phase 1 through phase 3.

Key ongoing/active development themes

• Earlier-stage disease: neoadjuvant or adjuvant strategies designed to reduce recurrence risk after complete resection or definitive therapy; this drives long-horizon trial readouts tied to survival endpoints.
• First-line metastatic EGFR-mutant NSCLC: ongoing work evaluates combinations and biomarkers to improve depth/duration versus osimertinib monotherapy.
• Resistance and progression settings: studies add or sequence targeted agents for acquired resistance (MET-driven, HER2-driven, or other bypass signaling) and test next-gen combinations.
• Combination therapy: most active combination areas are EGFR TKI plus chemotherapy or anti-angiogenic therapy in specific molecular subsets.

How to read the near-term pipeline risk

• Survival endpoint lag: adjuvant and peri-operative trials rely on disease-free survival (DFS) and overall survival (OS) maturity. The investment risk is timing, not feasibility.
• Biomarker selection: studies increasingly stratify by resistance mechanism and baseline co-mutations. This affects the probability of demonstrating statistically significant incremental benefit.
• Competition for lines of therapy: alternative EGFR TKIs and antibody-drug conjugates (ADCs) continue to pressure trial designs toward measurable endpoints (ORR, PFS, or DFS).

How large is the osimertinib mesylate market today, and where does growth come from?

Market structure

Osimertinib’s revenue base is concentrated in:

• NSCLC, EGFR-mutant (exon 19 deletion, L858R, and other activating mutations where indicated)
• Treatment-line penetration (first-line, post-progression, and earlier-stage segments)

Revenue is also supported by:

• Global expansion of testing and adoption of molecular diagnostics that identify activating EGFR mutations
• Crossover and sequencing effects: patients often receive osimertinib after earlier EGFR TKI exposure depending on local standards and prior treatments

Primary growth drivers

1. Line-of-therapy expansion
   Conversion from second-line to first-line use increases addressable patient volume and duration of therapy per patient.

2. Earlier-stage adoption
   If adjuvant or peri-operative programs show durable DFS/OS outcomes in label-relevant populations, osimertinib benefits from a larger recurring-treatment population.

3. Combination optimization
   Evidence-based combinations can extend use into subgroups with higher risk or resistance patterns.

Key demand constraints

• Patent and exclusivity calendar effects: as protection landscapes mature across major jurisdictions, generic and biosimilar competitors can compress pricing in local markets.
• Diagnostic eligibility and comorbidity patterns: uptake depends on EGFR testing rates, clinician adherence, and performance-status constraints.
• Treatment migration: novel therapies (including other TKIs, ADCs, and immune-chemotherapy regimens) can shift sequencing preferences.

What is the revenue outlook for osimertinib mesylate, and how is it shaped by patent expiry and competition?

Projection logic used for oncology TKI leaders

For high-cost oncology TKIs, forward revenue trajectories typically follow:

• Peak-and-decline dynamics post-maximum adoption
• Label expansions that delay decline
• Local patent expiry and exclusivity cliffs that accelerate it
• Sustained demand through sequencing even as pricing pressure increases

Market outlook (directional)

• Base case: gradual plateau with region-by-region pricing compression as bios and generics expand post-expiry; new indications (especially earlier-stage) can slow the decline by increasing total addressable treated patients.
• Upside case: earlier-stage programs mature with practice-changing efficacy signals, and combination regimens become guideline-adopted across biomarker-defined groups.
• Downside case: stronger competitor efficacy in first-line or resistance settings shifts sequencing away from osimertinib, and pricing compression occurs faster due to earlier local approvals of generics.

Competitive headwinds that matter in EGFR NSCLC

• Alternative EGFR TKIs with different resistance coverage and toxicity profiles
• ADC and chemo-IO regimens that can win lines of therapy based on survival data and guideline preferences
• Biomarker-driven selection that may reduce osimertinib’s share in molecular subgroups if competitors show superior outcomes there

What patent and exclusivity constraints will most influence revenue between now and the next decade?

Osimertinib is protected by a layered intellectual-property structure: compound patents, formulation/process patents, and additional jurisdictional protections (including SPCs/exclusivities where applicable). The practical impact on revenue is:

• Different effective expiry dates by country
• Early loss of market share in jurisdictions where generic launch is authorized
• Ongoing revenue lift when new indications extend exclusivity through supplementary protections

A revenue model should be stress-tested against:

• Local generic entry timing
• Switching behavior by payers and formularies
• Switch costs in oncology sequencing

What does this mean for investment-grade decisions on development strategy?

If you are investing in combinations

• Focus on biomarker-anchored resistance pathways where osimertinib remains mechanistically rational.
• Prioritize trials with earlier endpoints that can support label expansion quickly (PFS/ORR with mature DFS/OS follow-up).

If you are evaluating lifecycle extension

• The highest-value optionality sits in earlier-stage settings with recurrence reduction endpoints.
• Practice change depends on magnitude of benefit plus safety/tolerability under peri-operative or adjuvant regimens.

If you are assessing competitive entry risk

• Track payer behaviors where generics launch: oncology TKI switches are frequently policy-driven.
• Monitor guideline publications that lock in preferred sequencing.

Key Takeaways

• Osimertinib mesylate’s clinical strategy is dominated by EGFR-mutant NSCLC expansion across earlier lines and earlier-stage disease, plus resistance-focused combinations.
• Growth depends on line-of-therapy penetration, earlier-stage adoption, and biomarker-driven combination success; constraints come from diagnostic eligibility, treatment migration, and local pricing pressure.
• Revenue outlook follows peak-and-decline dynamics shaped by jurisdictional patent/exclusivity calendars and the speed of generic uptake, with upside from practice-changing new indications.

FAQs

1) What disease area is osimertinib mesylate’s clinical pipeline concentrated in?

Non-small cell lung cancer (NSCLC) with EGFR mutations.

2) What endpoints most influence near-to-medium term label expansion?

PFS/ORR in metastatic settings and DFS/OS maturity in adjuvant or peri-operative settings.

3) What combination types show the most trial activity?

Targeted combinations (EGFR TKI plus agents addressing bypass pathways such as MET/HER2) and regimen combinations that aim to improve durability versus monotherapy.

4) What drives revenue beyond first-line metastatic adoption?

Earlier-stage use, biomarker-defined sequencing, and combination regimens that maintain or extend treatment duration.

5) What is the biggest market risk factor for osimertinib mesylate?

Patent and exclusivity-driven generic entry that accelerates pricing compression in key jurisdictions.

---

References

[1] AstraZeneca. Tagrisso (osimertinib) prescribing information.
[2] ClinicalTrials.gov. Osimertinib-related interventional studies and records (accessed 2026-04-28).
[3] European Medicines Agency (EMA). Tagrisso assessment history and product information.
[4] U.S. Food and Drug Administration (FDA). Tagrisso (osimertinib) label and approval history.